Completed
PHASE2
INTERVENTIONAL
NCT00313781
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Interventions
Name:
CP-751,871
Type:
DRUG
Description:
CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
Name:
docetaxel
Type:
DRUG
Description:
Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
Name:
prednisone
Type:
DRUG
Description:
Prednisone is administered at a dose of 5 mg twice daily.
Name:
docetaxel
Type:
DRUG
Description:
Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
Name:
prednisone
Type:
DRUG
Description:
Prednisone is administered at a dose of 5 mg twice daily.
Primary Outcomes
Measure:
Percentage of Participants With Prostate Specific Antigen (PSA) Best Response
TimeFrame:
Baseline, Day 1 and Day 15 of each cycle, end of treatment (up to 28 days post last dose) and follow-up (monthly, up to 150 days post last dose)
Description:
Percentage of participants with PSA best response of either PSA normalization (PN) or partial PSA response (PR) relative to the total number of participants evaluable for response. PN was defined as PSA =\< 0.2 nanogram/milliliter (ng/ml) on 2 successive evaluations at least 3 weeks apart and no imaging or clinical evidence of disease progression. PP was defined as \>= 50% decrease in PSA from baseline on 2 successive evaluations at least 3 weeks apart and no imaging or clinical evidence of disease progression.
Trial Information
NCT ID
NCT00313781
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Pfizer
Last Updated
December 15, 2025